Mr. James Passin reports

BIOVAXYS TECHNOLOGY CORP. PROVIDES BI-WEEKLY MCTO STATUS UPDATE

Biovaxys Technology Corp. is providing this biweekly update on the status of the management cease trade order (MCTO) granted on March 3, 2026, by its principal regulator, the British Columbia Securities Commission (BCSC), under National Policy 12-203, Management Cease Trade Orders. The company announced on March 3, 2026, that it was unable to file its audited annual financial statements for the year ended Oct. 31, 2025, the related management's discussion and analysis (MD&A), and its Form 52-109FV1 chief executive officer and chief financial officer certifications of annual filings. Under National Instrument 51-102, Continuous Disclosure Obligations, the annual filings were required to be made not later than Feb. 28, 2026.

The company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the annual filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the company remains confident in its ability to complete the annual filings by April 28, 2026.

As a result of this further delay in filing the annual filings, the company anticipates it will not be in a position to file its interim financial statements for the three months ended Jan. 31, 2025, its management's discussion and analysis of financial statements for the three months ended Jan. 31, 2025, and the related filings. Under National Instrument 51-102, the interim filings are required to be made not later than April 1, 2026. The company anticipates filing the interim filings immediately after the filing of the annual filings.

Except as herein disclosed, there are no material changes to the information contained in the default announcement. In addition: (i) the company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue biweekly default status reports in the form of news releases, for so long as the company remains in default with the annual filings and/or interim filings; (ii) the company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the annual filings; (iii) the company confirms that, as of the date of this news release, the company is not subject to any insolvency proceedings; and (iv) there is no other material information concerning the affairs of the company that has not been generally disclosed.

The company confirms that while the MCTO is in effect, the general investing public will continue to be able to trade freely the company's listed common shares. However, the MCTO prohibits the company's chief executive officer and chief financial officer from trading securities of the company for so long as the annual filings are not filed. Additionally, the company will be prohibited from directly or indirectly issuing or acquiring securities from insiders or employees of the company until such time as the annual filings have been made and all continuous disclosure requirements have been met by the company, and the MCTO has been revoked.

About Biovaxys Technology Corp.

Biovaxys, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPXimmune-educating technology platform and its HapTenix tumour cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust and persistent immune response. The company's clinical-stage pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, in phase IIB clinical development for advanced relapsed-refractory diffuse large B-cell lymphoma (DLBCL) and platinum resistant ovarian cancer. MVP-S delivers antigenic peptides from the survivin family, a set of well-recognized cancer antigens commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T-cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications, as well as the activation of a targeted and sustained, survivin-specific anti-tumour immune response. Biovaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, MVP-S+letrozole for stages II to III HR+/HER2- breast cancer, DPX-RSV for respiratory syncytial virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix neoantigen tumour cell construct platform, for refractive late-stage ovarian cancer.

Biovaxys common shares are listed on the Canadian Securities Exchange under the stock symbol BIOV and trade on the Frankfurt Bourse under the symbol 5LB0 and in the U.S. on the OTC Markets under the symbol BVAXF).

We seek Safe Harbor.